Review





Similar Products

dota linagliptin he dpp4 targeted probe  (MedChemExpress)
94
MedChemExpress dota linagliptin he dpp4 targeted probe
Dota Linagliptin He Dpp4 Targeted Probe, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dota linagliptin he dpp4 targeted probe/product/MedChemExpress
Average 94 stars, based on 1 article reviews
dota linagliptin he dpp4 targeted probe - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
gene exp dpp4 mm00494538 m1  (Thermo Fisher)
89
Thermo Fisher gene exp dpp4 mm00494538 m1
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Gene Exp Dpp4 Mm00494538 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp dpp4 mm00494538 m1/product/Thermo Fisher
Average 89 stars, based on 1 article reviews
gene exp dpp4 mm00494538 m1 - by Bioz Stars, 2026-05
89/100 stars
  Buy from Supplier
anthine based dpp4 inhibitor linagliptin  (MedChemExpress)
94
MedChemExpress anthine based dpp4 inhibitor linagliptin
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Anthine Based Dpp4 Inhibitor Linagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anthine based dpp4 inhibitor linagliptin/product/MedChemExpress
Average 94 stars, based on 1 article reviews
anthine based dpp4 inhibitor linagliptin - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
mouse dpp4 cd26 antibody  (R&D Systems)
93
R&D Systems mouse dpp4 cd26 antibody
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Mouse Dpp4 Cd26 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse dpp4 cd26 antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
mouse dpp4 cd26 antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
human dpp4 cd26 antibody  (R&D Systems)
93
R&D Systems human dpp4 cd26 antibody
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Human Dpp4 Cd26 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dpp4 cd26 antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
human dpp4 cd26 antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
human cd26  (Creative BioMart)
90
Creative BioMart human cd26
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Human Cd26, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd26/product/Creative BioMart
Average 90 stars, based on 1 article reviews
human cd26 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
stock concentration  (Creative BioMart)
90
Creative BioMart stock concentration
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Stock Concentration, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stock concentration/product/Creative BioMart
Average 90 stars, based on 1 article reviews
stock concentration - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mouse anti dpp4 cd26  (Proteintech)
93
Proteintech mouse anti dpp4 cd26
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Mouse Anti Dpp4 Cd26, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti dpp4 cd26/product/Proteintech
Average 93 stars, based on 1 article reviews
mouse anti dpp4 cd26 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
anti cd26  (Proteintech)
94
Proteintech anti cd26
A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
Anti Cd26, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd26/product/Proteintech
Average 94 stars, based on 1 article reviews
anti cd26 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
gene exp dpp4 hs00897386 m1  (Thermo Fisher)
94
Thermo Fisher gene exp dpp4 hs00897386 m1
Quantification of ACE2 , dACE2 , TMPRSS2, NRP1, CTSL , BSG (CD147), <t>DPP4</t> (CD26), AXL , KREMEN1 , and ASGR1 gene expression. mRNA levels normalized to GAPDH (2 -ΔCT ) in ( a ) NHDF, NHEKs, RHE, and human skin samples and in ( b ) Caco-2/TC-7, Calu-3, and HaCaT cell lines. Gene expression was quantified by RT-qPCR in triplicate. Data represent the mean ± SEM from ( a ) 3 to 14 independent experiments using biological samples from different individuals and ( b ) 3 or 4 independent experiments from cultured cells. NHDF, normal human dermal fibroblast; NHEK, normal human epidermal keratinocyte; RHE, reconstructed human epidermis.
Gene Exp Dpp4 Hs00897386 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp dpp4 hs00897386 m1/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
gene exp dpp4 hs00897386 m1 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

Image Search Results


A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or Dpp4 in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study

doi: 10.1210/clinem/dgaf608

Figure Lengend Snippet: A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or Dpp4 in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.

Article Snippet: RNA was reverse-transcribed using RevertAid First Strand complementary DNA synthesis kit (Thermo Scientific). qPCR for Dpp4 (Mm00494538_m1), Gip (Mm00433601_m1) Hmgcr (Mm01282499_m1), Proglucagon ( Gcg ; Mm01269055_m1), Pcsk1 (Mm00479023_m1), Pyy (Mm00520715_m1), and 2 housekeeping genes ( Hprt [Mm03024075_m1] and Tbp [Mm01277042_m1]) was performed using TaqMan Expression PCR Master Mix (Life Technologies) using the ABI Prism 7900 HT system (Applied Biosystems).

Techniques: Clinical Proteomics, RNA Expression, Whisker Assay

Quantification of ACE2 , dACE2 , TMPRSS2, NRP1, CTSL , BSG (CD147), DPP4 (CD26), AXL , KREMEN1 , and ASGR1 gene expression. mRNA levels normalized to GAPDH (2 -ΔCT ) in ( a ) NHDF, NHEKs, RHE, and human skin samples and in ( b ) Caco-2/TC-7, Calu-3, and HaCaT cell lines. Gene expression was quantified by RT-qPCR in triplicate. Data represent the mean ± SEM from ( a ) 3 to 14 independent experiments using biological samples from different individuals and ( b ) 3 or 4 independent experiments from cultured cells. NHDF, normal human dermal fibroblast; NHEK, normal human epidermal keratinocyte; RHE, reconstructed human epidermis.

Journal: JID Innovations

Article Title: Human keratinocytes exhibit limited potential for SARS-CoV-2 infection despite ACE2 and mature cathepsin L expression

doi: 10.1016/j.xjidi.2025.100447

Figure Lengend Snippet: Quantification of ACE2 , dACE2 , TMPRSS2, NRP1, CTSL , BSG (CD147), DPP4 (CD26), AXL , KREMEN1 , and ASGR1 gene expression. mRNA levels normalized to GAPDH (2 -ΔCT ) in ( a ) NHDF, NHEKs, RHE, and human skin samples and in ( b ) Caco-2/TC-7, Calu-3, and HaCaT cell lines. Gene expression was quantified by RT-qPCR in triplicate. Data represent the mean ± SEM from ( a ) 3 to 14 independent experiments using biological samples from different individuals and ( b ) 3 or 4 independent experiments from cultured cells. NHDF, normal human dermal fibroblast; NHEK, normal human epidermal keratinocyte; RHE, reconstructed human epidermis.

Article Snippet: The following TaqMan MGB-FAM-labelled probes (Applied Biosystems, Thermo Fisher Scientific) were used for qPCR analysis: ACE2 (Hs01085340_m1), ACE2 + dACE2 (Hs01085333_m1), TMPRSS2 (Hs01120965_m1), NRP1 (Hs00826128_m1), CTSL (Hs00964650_m1), BSG (CD147) (Hs00936295_m1), DPP4 (Hs00897386_m1), AXL (Hs01064444_m1), KREMEN1 (Hs00230750_m1), ASGR1 (Hs01005019_m1), and reference gene GAPDH (Hs02758991_g1).

Techniques: Gene Expression, Quantitative RT-PCR, Cell Culture

Differential ACE2, TMPRSS2, NRP1, CTSL, CD147, AXL, and DPP4 protein expression. Whole-cell lysates of the indicated cells were analyzed by western blot using the following antibodies: ACE2 (mAb clone AC384), TMPRSS2 (mAb clone S20014A), NRP1 (mAb clone 14H4), CTSL (mAb clone 33/1), CD147 (mAb clone HIM6), AXL (polyclonal goat IgG, AF154), and DPP4 (polyclonal goat IgG, AF1180). ( a ) Representative immunoblots from 2 to 4 independent experiments. ( b ) Densitometric quantification normalized to actin, expressed as mean ± SEM from 2 to 4 independent experiments. CTSL, cathepsin L.

Journal: JID Innovations

Article Title: Human keratinocytes exhibit limited potential for SARS-CoV-2 infection despite ACE2 and mature cathepsin L expression

doi: 10.1016/j.xjidi.2025.100447

Figure Lengend Snippet: Differential ACE2, TMPRSS2, NRP1, CTSL, CD147, AXL, and DPP4 protein expression. Whole-cell lysates of the indicated cells were analyzed by western blot using the following antibodies: ACE2 (mAb clone AC384), TMPRSS2 (mAb clone S20014A), NRP1 (mAb clone 14H4), CTSL (mAb clone 33/1), CD147 (mAb clone HIM6), AXL (polyclonal goat IgG, AF154), and DPP4 (polyclonal goat IgG, AF1180). ( a ) Representative immunoblots from 2 to 4 independent experiments. ( b ) Densitometric quantification normalized to actin, expressed as mean ± SEM from 2 to 4 independent experiments. CTSL, cathepsin L.

Article Snippet: The following TaqMan MGB-FAM-labelled probes (Applied Biosystems, Thermo Fisher Scientific) were used for qPCR analysis: ACE2 (Hs01085340_m1), ACE2 + dACE2 (Hs01085333_m1), TMPRSS2 (Hs01120965_m1), NRP1 (Hs00826128_m1), CTSL (Hs00964650_m1), BSG (CD147) (Hs00936295_m1), DPP4 (Hs00897386_m1), AXL (Hs01064444_m1), KREMEN1 (Hs00230750_m1), ASGR1 (Hs01005019_m1), and reference gene GAPDH (Hs02758991_g1).

Techniques: Expressing, Western Blot

Validation of flow cytometry protocols and anti-ACE2 antibodies. ( a ) Comparison of cell detachment protocols. ( b ) Comparison of anti-ACE2 antibody staining by flow cytometry. ( c, d ) Binding of 2019-nCoV Spike Protein S1 (RBD) protein and blocking with anti-ACE2 antibody (mAb clone AC384) assessed by ( c ) flow cytometry and ( d ) immunofluorescence (red). Cell nuclei are stained with DAPI (white). Bar = 10 μm. Data are representative of 3 independent experiments. ( e ) Cell surface expression of ACE2 (mAb clone Poly5036), TMPRSS2 (mAb clone S20014A), NRP1 (mAb clone U21-1283), CD147 (mAb clone HIM6), AXL (mAb clone 108724), and DPP4 (mAb clone BA5b) in A549 cells. Data are representative of 2 independent experiments.

Journal: JID Innovations

Article Title: Human keratinocytes exhibit limited potential for SARS-CoV-2 infection despite ACE2 and mature cathepsin L expression

doi: 10.1016/j.xjidi.2025.100447

Figure Lengend Snippet: Validation of flow cytometry protocols and anti-ACE2 antibodies. ( a ) Comparison of cell detachment protocols. ( b ) Comparison of anti-ACE2 antibody staining by flow cytometry. ( c, d ) Binding of 2019-nCoV Spike Protein S1 (RBD) protein and blocking with anti-ACE2 antibody (mAb clone AC384) assessed by ( c ) flow cytometry and ( d ) immunofluorescence (red). Cell nuclei are stained with DAPI (white). Bar = 10 μm. Data are representative of 3 independent experiments. ( e ) Cell surface expression of ACE2 (mAb clone Poly5036), TMPRSS2 (mAb clone S20014A), NRP1 (mAb clone U21-1283), CD147 (mAb clone HIM6), AXL (mAb clone 108724), and DPP4 (mAb clone BA5b) in A549 cells. Data are representative of 2 independent experiments.

Article Snippet: The following TaqMan MGB-FAM-labelled probes (Applied Biosystems, Thermo Fisher Scientific) were used for qPCR analysis: ACE2 (Hs01085340_m1), ACE2 + dACE2 (Hs01085333_m1), TMPRSS2 (Hs01120965_m1), NRP1 (Hs00826128_m1), CTSL (Hs00964650_m1), BSG (CD147) (Hs00936295_m1), DPP4 (Hs00897386_m1), AXL (Hs01064444_m1), KREMEN1 (Hs00230750_m1), ASGR1 (Hs01005019_m1), and reference gene GAPDH (Hs02758991_g1).

Techniques: Biomarker Discovery, Flow Cytometry, Comparison, Staining, Binding Assay, Blocking Assay, Immunofluorescence, Expressing

Cell surface expression of ACE2, TMPRSS2, NRP1, CD147, AXL, and DPP4 receptors is associated with exclusive binding of SARS-CoV-2 Spike Protein S1 (RBD) to ACE2-expressing cells. ( a ) Flow cytometry analysis of cell surface expression of ACE2 (mAb clone Poly5036), TMPRSS2 (mAb clone S20014A), NRP1 (mAb clone U21-1283), CD147 (mAb clone HIM6), AXL (mAb clone 108724), and DPP4 (mAb clone BA5b) in the indicated cell lines and primary skin cells. Data are representative of 2–4 independent experiments. ( b, c ) Representative immunofluorescence microscopy images showing ( b ) ACE2 expression (mAb clone Poly5036) and ( c ) binding of 2019-nCoV Spike Protein S1 (RBD) in red. Cell nuclei are stained with DAPI (white). Bar = 10 μm. The proportions of cells expressing ACE2 and binding to spike are shown. Data are representative of at least 2 independent experiments. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Journal: JID Innovations

Article Title: Human keratinocytes exhibit limited potential for SARS-CoV-2 infection despite ACE2 and mature cathepsin L expression

doi: 10.1016/j.xjidi.2025.100447

Figure Lengend Snippet: Cell surface expression of ACE2, TMPRSS2, NRP1, CD147, AXL, and DPP4 receptors is associated with exclusive binding of SARS-CoV-2 Spike Protein S1 (RBD) to ACE2-expressing cells. ( a ) Flow cytometry analysis of cell surface expression of ACE2 (mAb clone Poly5036), TMPRSS2 (mAb clone S20014A), NRP1 (mAb clone U21-1283), CD147 (mAb clone HIM6), AXL (mAb clone 108724), and DPP4 (mAb clone BA5b) in the indicated cell lines and primary skin cells. Data are representative of 2–4 independent experiments. ( b, c ) Representative immunofluorescence microscopy images showing ( b ) ACE2 expression (mAb clone Poly5036) and ( c ) binding of 2019-nCoV Spike Protein S1 (RBD) in red. Cell nuclei are stained with DAPI (white). Bar = 10 μm. The proportions of cells expressing ACE2 and binding to spike are shown. Data are representative of at least 2 independent experiments. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Article Snippet: The following TaqMan MGB-FAM-labelled probes (Applied Biosystems, Thermo Fisher Scientific) were used for qPCR analysis: ACE2 (Hs01085340_m1), ACE2 + dACE2 (Hs01085333_m1), TMPRSS2 (Hs01120965_m1), NRP1 (Hs00826128_m1), CTSL (Hs00964650_m1), BSG (CD147) (Hs00936295_m1), DPP4 (Hs00897386_m1), AXL (Hs01064444_m1), KREMEN1 (Hs00230750_m1), ASGR1 (Hs01005019_m1), and reference gene GAPDH (Hs02758991_g1).

Techniques: Expressing, Binding Assay, Flow Cytometry, Immunofluorescence, Microscopy, Staining